Prelude Therapeutics, Lilly Partner To Evaluate PRT13722 In Breast Cancer Trial

Prelude Therapeutics (PRLD) and Eli Lilly (LLY) will collaborate to evaluate PRT13722 in a breast cancer trial. The Phase 1 study will test PRT13722 with Lilly's Verzenio and Inluriyo in HR+/HER2- breast cancer patients. Prelude's IND application was cleared by the FDA, with enrollment expected in Q4 2026. Preclinical data showed PRT13722's potential as a monotherapy and in combination therapies. PRLD's stock closed at $3.74 on Monday, up 6.42% in pre-market trading.

Original reporting
Published Oct 13, 2026, 12:33 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 13, 2026, 12:43 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PRLD
Bullish
high confidence
Mentioned
$PRLD · $LLY
Relevance
8/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$PRLDBullishMed
01

Why it matters

The IND clearance and partnership provide a clear path to clinical data, which could de‑risk the company and attract investors.

02

Market read

First disclosure of a new oncology trial partnership, likely to move Prelude's stock and modestly affect Lilly.

03

What to watch

Potential competition from other KAT6A/B inhibitors and the need for further funding.

Relevance 8/10Novelty 8/10Timing: pre‑market today

Background

Prelude Therapeutics is a clinical‑stage biotech developing novel epigenetic therapies; Eli Lilly is a large pharma with established breast‑cancer drugs.

Company-level read

Ticker impact

$PRLDBullishHigh confidence
Context

Prelude Therapeutics announced a new clinical trial collaboration with Eli Lilly and received FDA IND clearance for PRT13722.

Expected impact

likely upside as investors price in potential future approvals

Evidence & confidence

First report of IND clearance and partnership with a major pharma partner.

$LLYNeutralMedium confidence
Context

Eli Lilly will supply Verzenio and Inluriyo for Prelude's Phase 1 study of PRT13722.

Expected impact

likely limited impact, modest upside if trial shows promise

Evidence & confidence

Lilly is a party to the deal but the news centers on Prelude's trial progress.

Market effects

Adds to momentum in the oncology biotech sector as new KAT6A degrader enters trials.

US biotech market may see modest uplift from the partnership announcement.

Limited to investors focused on US biotech and oncology pipelines.

Counterpoint

The trial may face delays or fail to differentiate, limiting upside for Prelude.

Key entities

  • Prelude Therapeutics

    Developer of PRT13722, a KAT6A selective degrader.

  • Eli Lilly and Company

    Supplier of Verzenio and Inluriyo for the combination trial.

Related articles

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$LLYMed

Lilly's EloraTZP Brought Up to 77% of Adults With Diabetes to Normal Blood Sugar in Phase 2 Trial

Eli Lilly's experimental drug EloraTZP showed promising results in a Phase 2 trial, with up to 77% of adults with type 2 diabetes and obesity achieving normal blood sugar levels and 60% no longer meeting obesity criteria after 48 weeks. Participants in the best-performing group lost an average of 54.1 pounds, or 23.3% of their body weight. The trial did not test long-term safety or results after stopping the drug.

$LLYMedAI 8/10

Stipple Bio Signs Up to $5.9B Oncology Deal With Eli Lilly

Eli Lilly has partnered with private biotech firm Stipple Bio on an oncology research deal potentially worth up to $5.9B. Stipple's technology aims to identify cancer-specific molecules, aiding Lilly's development of targeted therapies. Stipple will receive milestone payments, royalties, and an equity investment, while Lilly gains exclusive rights to resulting products. Stipple is also developing its own oncology pipeline, including STP-100, set for Phase 1 trials in 2027.